

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
SCOPE OF REPORT .....	2
INTENDED AUDIENCE.....	2
INFORMATION SOURCES AND METHODOLOGY.....	2
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS .....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER .....	3
 CHAPTER TWO: SUMMARY.....	 4
<i>SUMMARY TABLE GLOBAL MARKET FORECAST FOR     PERSONALIZED MEDICINE, BY TECHNOLOGY, THROUGH 2014     (\$ MILLIONS)</i> .....	  4
<i>SUMMARY FIGURE GLOBAL MARKET FORECAST FOR     PERSONALIZED MEDICINE, BY TECHNOLOGY, 2007-2014     (\$ MILLIONS)</i> .....	  5
 CHAPTER THREE: MARKET OVERVIEW .....	 6
<i>FIGURE 1 PERSONALIZED MEDICINE VS CONVENTIONAL     TREATMENTS</i> .....	 7
<i>FIGURE 2 FOCUS OF PERSONALIZED MEDICINE</i> .....	8
CHANGING TRENDS: FROM BLOCKBUSTER MODEL TO PERSONALIZED MODEL.....	9
<i>FIGURE 3 PERSONALIZED MEDICINE VS BLOCKBUSTER DRUGS</i> .....	10
MAJOR MARKET DRIVERS .....	11
ACCURACY AND PREVENTIVE DIAGNOSIS.....	11
COST-EFFECTIVE IN LONG RUN.....	11
RECUPERATIVE BENEFITS.....	11
MORE EFFECTIVE THAN CONVENTIONAL TREATMENTS .....	11
MARKET RESTRAINTS .....	11
RELUCTANCE AMONG PHARMACEUTICAL COMPANIES .....	12
LEGAL ISSUES DUE TO INTELLECTUAL PROPERTY RIGHTS.....	12
LACK OF INSURANCE COVERAGE .....	12
<i>FIGURE 4 MAJOR MARKET TRENDS IN PERSONALIZED MEDICINE</i> .....	13
STAKEHOLDERS' OPPORTUNITIES.....	13
<i>FIGURE 5 PARTICIPATION OF STAKEHOLDERS</i> .....	14
<i>TABLE 1 GLOBAL MARKET FOR STAKEHOLDERS, THROUGH 2014     (\$ MILLIONS)</i> .....	 15
DEFINING THE OVERALL PERSONALIZED MEDICINE MARKET .....	15
<i>FIGURE 6 MARKET STRUCTURE FOR PERSONALIZED MEDICINE</i> .....	15

DEFINING THE PERSONALIZED MEDICINE TECHNOLOGY MARKET .....	16
<i>FIGURE 7 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, 2007-2014 (\$ MILLIONS)</i> .....	16
DEFINING THE PERSONALIZED MEDICINE PRODUCTS AND SERVICES MARKET .....	17
<i>TABLE 2 GLOBAL PERSONALIZED MEDICINE MARKET BY PRODUCTS AND SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	17
DEFINING THE PERSONALIZED MEDICINE APPLICATIONS MARKET .....	18
<i>TABLE 3 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATION, THROUGH 2014 (\$ MILLIONS)</i> .....	18
DEFINING THE PERSONALIZED MEDICINE MARKET BY GEOGRAPHY .....	18
<i>FIGURE 8 GLOBAL MARKETS FOR PERSONALIZED MEDICINE, 2009 (%)</i> .....	19
PATENT ANALYSIS .....	19
<i>FIGURE 9 NUMBER OF PATENTS ISSUED, JAN. 2004–APR. 2009</i> .....	20
 CHAPTER FOUR: GLOBAL PERSONALIZED MEDICINE MARKET BY TECHNOLOGY .....	 21
<i>FIGURE 10 POSITIONING VARIOUS TECHNOLOGIES IN THE MARKET FOR PERSONALIZED MEDICINE</i> .....	22
ANALYSIS OF PATENTS BY TECHNOLOGY .....	23
<i>FIGURE 11 SHARE OF PATENTS BY TECHNOLOGY (%)</i> .....	23
GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE .....	24
<i>TABLE 4 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	24
<i>TABLE 5 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	25
MARKET DRIVERS.....	25
Increased Health Awareness and Preventive Diagnosis to Boost the Demand for Pharmacogenomics.....	25
Increased Revenue Opportunities for Diagnostic and Drug Companies .....	25
Enhanced Treatment and Better Drug Efficacy Rate.....	25
MARKET RESTRAINTS .....	26
Intellectual Property Rights Problem.....	26
Legal Issues within Nations.....	26
PHARMACOGENOMIC SERVICES MARKET .....	26
<i>TABLE 6 GLOBAL PHARMACOGENOMICS MARKET IN PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	27

<i>TABLE 7 GLOBAL PHARMAOGENOMICS SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	27
Global Market for SNP Genotyping.....	27
Cost Effective Sequencing Boosts Demand.....	28
Oligopoly Market Restrains Entry of New Companies.....	28
Global Market for SNP Genotyping Services .....	28
<i>TABLE 8 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY DIAGNOSIS METHODS, THROUGH 2014 (\$ MILLIONS)</i> .....	29
<i>TABLE 9 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	29
Global Market for SNP Genotyping Products .....	29
<i>TABLE 10 GLOBAL SNP GENOTYPING MARKET IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 (\$ MILLIONS)</i> .....	30
Major Companies and Products .....	30
<i>TABLE 11 MAJOR PRODUCTS IN SNP GENOTYPING</i> .....	30
Global Market for Pharmacogenomic Drug Discovery and Delivery.....	30
<i>TABLE 12 GLOBAL DRUG DISCOVERY AND DELIVERY MARKET IN PHARMAOGENOMICS, THROUGH 2014 (\$ MILLIONS)</i> .....	31
Market for SSR–Based Diagnosis.....	31
<i>TABLE 13 GLOBAL SSR BASED DIAGNOSIS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	32
Market for VNTRs–Based Diagnosis.....	32
<i>TABLE 14 GLOBAL VNTR BASED DIAGNOSIS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	32
Global Market for Pharmacogenomic Therapy .....	33
<i>TABLE 15 GLOBAL PHARMAOGENOMIC THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	33
Global Market for Other Pharmacogenomic Services.....	33
TOP COMPANIES .....	33
<i>TABLE 16 MAJOR COMPANIES AND RESPECTIVE PRODUCTS IN PHARMAOGENOMIC SERVICES</i> .....	34
PHARMAOGENOMIC PRODUCTS MARKET .....	34
<i>TABLE 17 GLOBAL PHARMAOGENOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 (\$ MILLIONS)</i> .....	34
<i>TABLE 18 GLOBAL PHARMAOGENOMICS PRODUCTS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	35
Markets for Pharmacogenomic Drugs .....	35
<i>TABLE 19 GLOBAL PHARMAOGENOMICS DRUGS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	35
Markets for Equipment in Pharmacogenomics .....	36

<i>TABLE 20 GLOBAL PHARMACOGENOMICS EQUIPMENT MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	36
MAJOR TECHNIQUES .....	36
<i>TABLE 21 GLOBAL MARKET FOR MAJOR PHARMACOGENOMIC TECHNIQUES IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	37
GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE .....	37
<i>TABLE 22 GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	38
<i>TABLE 23 GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	38
MARKET DRIVERS.....	38
Superior Diagnostic Results with Protein Studies.....	38
High Revenue Generation Attracts More Market Players .....	39
MARKET RESTRAINTS .....	39
Continuous Change in Protein Formation Makes it a Costly Treatment .....	39
TOP COMPANIES .....	39
<i>TABLE 24 MAJOR PRODUCTS IN PHARMACOPROTEOMICS</i> .....	39
MARKET FOR PHARMACOPROTEOMICS SERVICES.....	40
<i>TABLE 25 GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	40
<i>TABLE 26 GLOBAL PHARMACOPROTEOMICS SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	41
PHARMACOPROTEOMIC PRODUCTS .....	41
<i>TABLE 27 GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 (\$ MILLIONS)</i> .....	41
<i>TABLE 28 GLOBAL PHARMACOPROTEOMICS PRODUCTS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	42
<i>TABLE 29 GLOBAL PHARMACOPROTEOMICS DRUGS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	42
MAJOR TECHNOLOGIES .....	43
<i>TABLE 30 GLOBAL PHARMACOPROTEOMICS MARKET IN PERSONALIZED MEDICINE BY MAJOR TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	43
GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE .....	43
<i>TABLE 31 GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	44

<i>TABLE 32 GLOBAL STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	44
MARKET DRIVERS.....	45
Highly Untapped Market .....	45
Multiple Treatments with One Stem Cell .....	45
Government Appreciation in the U.S. for Embryonic Stem Cell Research.....	45
MARKET RESTRAINTS .....	45
Time Consuming Treatment .....	45
Side Effects .....	46
TOP COMPANIES .....	46
<i>TABLE 33 MAIN COMPANIES AND PRODUCTS IN STEM CELL THERAPY</i> .....	46
<i>TABLE 34 RECENT PRODUCTS IN STEM CELL THERAPY</i> .....	46
ADULT STEM CELL THERAPY .....	47
<i>TABLE 35 GLOBAL ADULT STEM CELL THERAPY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	47
Market Drivers .....	47
Enhanced Treatment for Spinal Cord Injury and Diseases such as Cancer.....	47
Federal Funding in the U.S. for Adult Stem Cell Therapy .....	48
Market Restraints .....	48
Stem Cell Therapy Requires Frequent Treatment.....	48
EMBRYONIC STEM CELL THERAPY .....	48
Market Drivers .....	49
Enhanced Curative Potential Will Attract More Customers .....	49
Sufficient Knowledge on many Ranges of Stem Cells.....	49
Market Restraints .....	49
Religious and Political Issues.....	49
OTHER TECHNIQUES .....	49
GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE .....	50
<i>TABLE 36 GLOBAL POINT OF CARE MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	50
MARKET DRIVERS.....	51
Fast, Easy, and Exact Personalized Care.....	51
Developed Technology Paves the Way for a Developed Market .....	51
MARKET RESTRAINTS .....	51
Time-Consuming Realization of Insurance Policies.....	51
TOP COMPANIES AND THEIR PRODUCTS .....	51

<i>TABLE 37 TOP COMPANIES AND THEIR PRODUCTS IN POINT OF CARE</i> .....	51
<i>TABLE 37 (CONTINUED)</i> .....	52
<i>TABLE 38 NEW TECHNOLOGIES IN POINT OF CARE</i> .....	52
GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE .....	52
<i>TABLE 39 GLOBAL METABOLOMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	53
MARKET DRIVERS.....	53
Enhanced R&D in Drug Discovery Process.....	53
Competitive Advantage and Less Regulatory Hurdles in Final Drug Delivery .....	53
MARKET RESTRAINTS .....	54
Adopted by Fewer Companies.....	54
TOP COMPANIES .....	54
<i>TABLE 40 MAJOR COMPANIES AND THEIR PRODUCTS</i> .....	54
GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE .....	54
<i>TABLE 41 GLOBAL PHARMACOGENETICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	55
MARKET DRIVERS.....	55
Preventive and Curative Treatments Use Pharmacogenetic Technique .....	55
Enhanced Drugs for Diseases such as Cancer/Cardiovascular Problems .....	55
MARKET RESTRAINTS .....	56
High Cost .....	56
TOP COMPANIES .....	56
<i>TABLE 42 MAIN PRODUCTS IN PHARMACOGENETICS</i> .....	56
GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE .....	56
<i>TABLE 43 GLOBAL PHARMACOKINETICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	57
MARKET DRIVERS.....	57
Better Evaluation of the Body's Response to the Drug.....	57
Quantitative Results Make it User Friendly for Patients .....	57
Untapped Market Means Potential Growth for Companies.....	58
MARKET RESTRAINTS .....	58
Assumptions of Mathematical Models Can Give Unwanted Results .....	58
Costly Treatment Hampers Market Growth.....	58
TOP COMPANIES .....	58
<i>TABLE 44 MAIN PRODUCTS IN PHARMACOKINETICS</i> .....	59

GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE .....	59
<i>TABLE 45 GLOBAL PHARMACODYNAMICS MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>59</i>
CHAPTER FIVE: GLOBAL MARKET FOR PERSONALIZED MEDICINE	
BY SERVICES.....	61
<i>TABLE 46 GLOBAL PERSONALIZED MEDICINE MARKET BY SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>61</i>
<i>TABLE 47 GLOBAL PERSONALIZED MEDICINE SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>62</i>
GLOBAL MARKET FOR DRUG DEVELOPMENT/DRUG DELIVERY SERVICE .....	62
<i>TABLE 48 GLOBAL DRUG DEVELOPMENT AND DELIVERY MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>62</i>
MARKET DRIVERS.....	63
Shift of Trend from Blockbuster Drugs to Tailored Drugs .....	63
Higher Efficacy of Drugs with Personalized Medicine.....	63
MARKET RESTRAINTS .....	63
Expensive Drugs In Comparison To Blockbuster Drugs .....	63
TOP COMPANIES .....	63
GLOBAL MARKET FOR DIAGNOSIS.....	63
<i>TABLE 49 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC SERVICES MARKET, BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>64</i>
<i>TABLE 50 GLOBAL PERSONALIZED MEDICINE DIAGNOSTIC SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>65</i>
PHARMACOGENOMICS BASED DIAGNOSIS .....	65
<i>TABLE 51 GLOBAL PHARMACOGENOMIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>66</i>
Market Drivers .....	66
Individual Gene Tests are Increasing Revenues for Diagnostic Players.....	66
Market Restraints .....	66
Rapidly Evolving Technology is Not Aligned to Fixed Regulatory System .....	66
PHARMACOPROTEOMICS BASED DIAGNOSIS.....	66
<i>TABLE 52 GLOBAL PHARMACOPROTEOMIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	<i>67</i>
Market Drivers .....	67
In–Depth Research Provides a Lot of Information for Diagnosis .....	67
Market Restraints .....	67

Costly Treatment Due to Requirement of Continuous Monitoring of Changing Protein Formation .....	67
PHARMACOGENETICS BASED DIAGNOSIS .....	68
<i>TABLE 53 GLOBAL PHARMACOGENETIC DIAGNOSTIC SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	68
GLOBAL MARKET FOR MONITORING AND THERAPY SERVICES .....	68
MONITORING SERVICES .....	68
<i>TABLE 54 GLOBAL PERSONALIZED MEDICINE MONITORING SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	69
THERAPEUTIC SERVICES .....	69
<i>TABLE 55 GLOBAL PERSONALIZED MEDICINE THERAPEUTIC SERVICES MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	69
GLOBAL MARKET FOR OTHER SERVICES .....	69
<i>TABLE 56 GLOBAL OTHER SERVICES MARKET IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	70
CHAPTER SIX: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY	
PRODUCTS .....	71
<i>TABLE 57 GLOBAL PERSONALIZED MEDICINE MARKET BY PRODUCTS, THROUGH 2014 (\$ MILLIONS)</i> .....	71
<i>TABLE 58 GLOBAL PERSONALIZED MEDICINE PRODUCTS MARKET, THROUGH 2014 (\$ MILLIONS)</i> .....	72
GLOBAL PERSONALIZED MEDICINE MARKET FOR DIAGNOSTICS EQUIPMENT .....	72
<i>TABLE 59 GLOBAL MARKET FOR DIAGNOSTIC EQUIPMENT IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	72
MARKET DRIVERS .....	73
Increased Demand for Genetic and Proteomic Tests .....	73
MARKET RESTRAINTS .....	73
Fast Changing Technology .....	73
<i>TABLE 60 GLOBAL MARKET FOR MONITORING AND THERAPEUTIC EQUIPMENT IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	73
MARKET DRIVERS .....	74
Improved Technology Along with Low-Cost Monitoring and Therapeutic Devices .....	74
GLOBAL PERSONALIZED MEDICINE MARKET FOR BIOINFORMATICS PRODUCTS .....	74
<i>TABLE 61 GLOBAL MARKET FOR BIOINFORMATICS IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	74
MARKET DRIVERS .....	75
Bioinformatics Reduces Cost of Drug Development .....	75
MARKET RESTRAINTS .....	75



High Initial Investment Hinders Small and Medium Sized Companies .....	75
GLOBAL PERSONALIZED MEDICINE MARKET FOR DRUGS .....	75
TABLE 62 GLOBAL MARKET FORECAST FOR DRUGS IN PERSONALIZED MEDICINE BY PRODUCTS, THROUGH 2014 (\$ MILLIONS).....	76
TABLE 63 GLOBAL MARKET FORECAST FOR DRUGS IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS).....	76
DRUG STAGES .....	76
FIGURE 12 PRODUCT LIFE CYCLE FOR PERSONALIZED MEDICINE PRODUCTS.....	77
GLEEVEC.....	78
TABLE 64 GLOBAL MARKET FORECAST FOR GLEEVAC IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS).....	78
Market Drivers .....	78
Higher Efficacy of Gleevec Gives it a Large Consumer Base .....	78
Gleevec as a Pill Makes it Easy to Consume .....	79
Assistance for Reimbursement from Insurance Companies.....	79
Market Restraints .....	79
High Drug Cost is Affecting Market Growth.....	79
Inherent Side Effects of Gleevec .....	79
HERCEPTIN .....	79
TABLE 65 GLOBAL MARKET FORECAST FOR HERCEPTIN IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS).....	80
Market Drivers .....	80
Enhanced Treatment with Reduced Risk of Reoccurrence of Breast Cancer .....	80
Market Restraints .....	80
Tailor Made Herceptin Still Carries Inherent Side Effects .....	80
ZIAGEN .....	81
TABLE 66 GLOBAL MARKET FORECAST FOR ZIAGEN IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS).....	81
Market Drivers .....	81
Customizable for Children.....	81
Market Restraints .....	82
Treatment with Ziagen Cannot Be Restarted .....	82
IRESSA AND TARCEVA.....	82
Iressa.....	82
Market Drivers.....	82
• Iressa in Pills Makes it User Friendly.....	82
Market Restraints.....	83

• FDA Ban on Iressa Is Keeping it Away from the U.S. Market .....	83
Tarceva.....	83
<i>TABLE 67 GLOBAL MARKET FORECAST FOR IRESSA &amp; TARCEVA IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	83
ERBITUX.....	84
<i>TABLE 68 GLOBOL MARKET FORECAST FOR ERBITUX IN PERSONALIZED MEDICINE THROUGH 2014 (\$ MILLIONS)</i> .....	84
Market Drivers .....	85
Multiple Cancers Are Treated with Erbitux, which Gives it a Large Patient Base .....	85
Enhanced Survival Results when Radiotherapy Is Combined with Erbitux.....	85
OTHERS .....	85
<i>TABLE 69 GLOBAL MARKET FORECAST FOR OTHER DRUGS IN PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS)</i> .....	85
 CHAPTER SEVEN: GLOBAL MARKET FOR PERSONALIZED MEDICINE BY APPLICATIONS.....	86
<i>FIGURE 13 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATION, THROUGH 2014 (\$ BILLIONS)</i> .....	87
PERSONALIZED MEDICINE MARKET FOR CARDIOVASCULAR DISEASE.....	87
<i>TABLE 70 GLOBAL MARKET FORECAST FOR TREATMENT OF CARDIOVASCULAR DISEASES, THROUGH 2014 (\$ MILLIONS)</i> .....	88
MARKET DRIVERS.....	88
Possible Preventive Measure .....	88
MARKET RESTRAINTS .....	89
Lack of Proactive Approach for Early Diagnosis.....	89
PERSONALIZED MEDICINE MARKET FOR BREAST CANCER.....	89
<i>TABLE 71 GLOBAL MARKET FORECAST FOR BREAST CANCER TREATMENT THROUGH 2014 (\$ MILLIONS)</i> .....	90
MARKET DRIVERS.....	90
Fewer Side Effects with Personalized Medicine .....	90
MARKET RESTRAINTS .....	90
Resistance to Adopting New Methods of Treatment.....	90
RECENT DEVELOPMENTS .....	90
<i>TABLE 72 RECENT DEVELOPMENTS IN TREATMENT OF BREAST CANCER</i> .....	91
PERSONALIZED MEDICINE MARKET FOR LEUKEMIA.....	91
<i>TABLE 73 GLOBAL MARKET FORECAST FOR LEUKEMIA TRETAMENT THROUGH 2014 (\$ MILLIONS)</i> .....	92
MARKET DRIVERS.....	92
Huge Market Potential for Leukemia.....	92
MARKET RESTRAINTS .....	92

Lack of Awareness that Surgery Is the Only Way to Treat Leukemia .....	92
PERSONALIZED MEDICINE MARKET FOR LUNG CANCER .....	92
<b>TABLE 74 GLOBAL MARKET FORECAST FOR LUNG CANCER TREATMENT, THROUGH 2014 (\$ MILLIONS)</b> .....	<b>93</b>
MARKET DRIVERS.....	93
Higher Efficiency Than Conventional Lung Cancer Treatment.....	93
Availability of Drugs in the Form of Pills Makes Treatment User Friendly.....	93
MARKET RESTRAINTS .....	94
Lack of FDA Approval for Certain Personalized Drugs.....	94
RECENT DEVELOPMENTS .....	94
PERSONALIZED MEDICINE MARKET FOR TREATING HIV/AIDS.....	94
<b>TABLE 75 GLOBAL MARKET FORECAST FOR AIDS TREATMENT THROUGH 2014 (\$ MILLIONS)</b> .....	<b>95</b>
MARKET DRIVERS.....	95
Personalized Medicine Improves Life Expectancy of a Patient .....	95
Easy Reimbursement for Aids Patients from NGOs/Government Organizations .....	95
MARKET RESTRAINTS .....	95
Lack of Awareness Among Patients .....	95
PERSONALIZED MEDICINE MARKET FOR NEUROLOGICAL DISORDERS .....	96
<b>TABLE 76 GLOBAL MARKET FORECAST FOR TREATING NEUROLOGICAL DISORDERS, THROUGH 2014 (\$ MILLIONS)</b> .....	<b>96</b>
MARKET DRIVERS.....	96
Enhanced Treatment.....	96
MARKET RESTRAINTS .....	97
Apprehensive to Try Out New Medications .....	97
PERSONALIZED MEDICINE MARKET FOR DIABETES .....	97
<b>TABLE 77 GLOBAL MARKET FORECAST FOR TREATMENT OF DIABETES, THROUGH 2014 (\$ MILLIONS)</b> .....	<b>97</b>
MARKET DRIVERS.....	98
Early Diagnosis Can Help Prevent Diabetes .....	98
MARKET RESTRAINTS .....	98
Casual Approach towards Diabetes.....	98
RECENT DEVELOPMENTS .....	98
<b>TABLE 78 RECENT DEVELOPMENTS IN TREATING DIABETES</b> .....	<b>98</b>
PERSONALIZED MEDICINE MARKET FOR ASTHMA .....	99
<b>TABLE 79 GLOBAL MARKET FORECAST FOR TREATING ASTHMA, THROUGH 2014 (\$ MILLIONS)</b> .....	<b>99</b>
MARKET DRIVERS.....	99

Every Asthma Case Is Distinct, Needs Custom–Tailored Treatment.....	99
Asthma Treatment Needs Regular Monitoring.....	100
OTHER APPLICATIONS .....	100
TABLE 80 GLOBAL MARKET FORECAST FOR TREATING OTHER CANCER/TUMOR, THROUGH 2014 (\$ MILLIONS) .....	100
TABLE 81 GLOBAL MARKET FORECAST FOR TREATING OTHER DISEASES, THROUGH 2014 (\$ MILLIONS).....	101
CHAPTER EIGHT: GLOBAL PERSONALIZED MARKET BY GEOGRAPHY....	102
TABLE 82 GLOBAL MARKET FORECAST FOR PERSONALIZED MEDICINE, THROUGH 2014 (\$ MILLIONS).....	102
ANALYSIS OF PATENTS BY GEOGRAPHY .....	102
FIGURE 14 NUMBER OF PATENTS ISSUED, BY GEOGRAPHY, JAN 2004 – APR 2009).....	103
PERSONALIZED MEDICINE MARKET IN NORTH AMERICA .....	103
GOVERNMENTAL SUPPORT.....	104
DEMOGRAPHIC STATUS .....	104
RECESSION.....	104
NORTH AMERICAN MARKET FOR PERSONALIZED MEDICINE TECHNOLOGIES .....	104
TABLE 83 NORTH AMERICAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS).....	105
NORTH AMERICAN MARKET FOR PERSONALIZED MEDICINE SERVICES.....	105
TABLE 84 NORTH AMERICAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY SERVICES, THROUGH 2014 (\$ MILLIONS).....	105
NORTH AMERICAN MARKET FOR PERSONALIZED MEDICINE PRODUCTS .....	106
TABLE 85 NORTH AMERICAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY PRODUCTS, THROUGH 2014 (\$ MILLIONS).....	106
NORTH AMERICAN MARKET FOR APPLICATIONS OF PERSONALIZED MEDICINE .....	106
TABLE 86 NORTH AMERICAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATIONS, THROUGH 2014 (\$ MILLIONS).....	107
RECENT DEVELOPMENTS .....	107
TABLE 87 RECENT MERGERS AND ACQUISITIONS IN THE NORTH AMERICAN MARKET.....	107
TABLE 87 (CONTINUED).....	108
PERSONALIZED MEDICINE MARKET IN EUROPE.....	108

<i>FIGURE 15 EUROPEAN MARKETS FOR PERSONALIZED MEDICINE, 2009 (%)</i> .....	108
<i>FIGURE 15 (CONTINUED)</i> .....	109
EUROPEAN UNION IS FUELING THE GROWTH OF PERSONALIZED MEDICINE IN EUROPE .....	109
HIGH PER CAPITA EXPENDITURE ON HEALTHCARE .....	109
EUROPEAN MARKET FOR PERSONALIZED MEDICINE TECHNOLOGIES .....	109
<i>TABLE 88 EUROPEAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	110
EUROPEAN MARKET FOR PERSONALIZED MEDICINE SERVICES .....	110
<i>TABLE 89 EUROPEAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY SERVICES, THROUGH 2014 (\$ MILLIONS)</i> .....	110
EUROPEAN MARKET FOR PERSONALIZED MEDICINE PRODUCTS.....	110
<i>TABLE 90 EUROPEAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY PRODUCTS, THROUGH 2014 (\$ MILLIONS)</i> .....	111
EUROPEAN MARKET FOR APPLICATIONS OF PERSONALIZED MEDICINE .....	111
<i>TABLE 91 EUROPEAN MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATIONS, THROUGH 2014 (\$ MILLIONS)</i> .....	111
RECENT DEVELOPMENTS .....	112
<i>TABLE 92 MAJOR ACTIVITIES IN EUROPEAN MARKET</i> .....	112
PERSONALIZED MEDICINE MARKET IN ASIA PACIFIC .....	112
MOST DENSELY POPULATED REGION WITH FAST DEVELOPING COUNTRIES LIKE CHINA AND INDIA.....	112
A LARGE NUMBER OF PATIENTS WITH UNMET MEDICAL REQUIREMENTS IN THIS REGION.....	113
LOW PER CAPITA EXPENDITURE ON HEALTHCARE IN COMPARISON TO OTHER REGIONS.....	113
ASIA PACIFIC MARKET FOR PERSONALIZED MEDICINE TECHNOLOGIES.....	113
<i>TABLE 93 ASIA PACIFIC MARKET FORECAST FOR PERSONALIZED MEDICINE, BY TECHNOLOGY, THROUGH 2014 (\$ MILLIONS)</i> .....	113
ASIA PACIFIC MARKET FOR PERSONALIZED MEDICINE BY PRODUCTS AND SERVICES .....	114
<i>FIGURE 16 ASIA PACIFIC MARKET FORECAST FOR PERSONALIZED MEDICINE, BY PRODUCTS &amp; SERVICES, THROUGH 2014 (\$ BILLIONS)</i> .....	114
ASIA PACIFIC MARKET FOR APPLICATIONS OF PERSONALIZED MEDICINE .....	115
<i>TABLE 94 ASIA PACIFIC MARKET FORECAST FOR PERSONALIZED MEDICINE, BY APPLICATIONS, THROUGH 2014 (\$ MILLIONS)</i> .....	115

RECENT DEVELOPMENTS .....	115
<i>TABLE 95 IMPORTANT ACTIVITIES IN ASIA PACIFIC MARKET</i> .....	116
<i>TABLE 96 NEW PRODUCT LAUNCHES IN ASIA PACIFIC MARKET</i> .....	116
PERSONALIZED MEDICINE MARKET IN THE REST OF WORLD (ROW) .....	116
UNAFFECTED BY RECESSION, THE MIDDLE EAST IS BOOSTING THE GROWTH .....	117
LARGE NUMBER OF AIDS PATIENT IN AFRICAN COUNTRIES .....	117
POLITICAL AND ECONOMIC INSTABILITY IN MOST OF THE COUNTRIES .....	117
CHAPTER NINE: COMPANY PROFILES .....	118
ABBOTT .....	118
OVERVIEW .....	118
<i>TABLE 97 PRODUCT PORTFOLIO OF ABBOTT</i> .....	118
<i>TABLE 97 (CONTINUED)</i> .....	119
STRATEGY .....	119
AFFYMETRIX .....	120
OVERVIEW .....	120
<i>TABLE 98 PRODUCT PORTFOLIO OF AFFYMETRIX (MICROARRAYS)</i> .....	120
<i>TABLE 98 (CONTINUED)</i> .....	121
<i>TABLE 98 (CONTINUED)</i> .....	122
<i>TABLE 99 PRODUCT PORTFOLIO OF AFFYMETRIX (REAGENTS &amp; ASSAYS)</i> .....	122
<i>TABLE 99 (CONTINUED)</i> .....	123
STRATEGY .....	123
AGENDIA BV .....	123
OVERVIEW .....	124
<i>TABLE 100 PRODUCT PORTFOLIO OF AGENDIA BV</i> .....	124
STRATEGY .....	124
ASURAGEN .....	124
OVERVIEW .....	124
<i>TABLE 101 PRODUCT PORTFOLIO OF ASURAGEN</i> .....	125
STRATEGY .....	125
BAYER HEALTHCARE .....	126
<i>TABLE 102 PRODUCT PORTFOLIO OF BAYER HEALTHCARE</i> .....	126
STRATEGY .....	126
BIOGEN (IDEC) .....	127
OVERVIEW .....	127
<i>TABLE 103 PRODUCT PORTFOLIO OF BIOGEN (IDEC)</i> .....	127
STRATEGY .....	127
BRISTOL-MYERS SQUIBB .....	128
OVERVIEW .....	128
<i>TABLE 104 PRODUCT PORTFOLIO OF BRISTOL-MYERS SQUIBB</i> .....	128

STRATEGY.....	128
CELERA DIAGNOSTICS.....	129
OVERVIEW.....	129
<i>TABLE 105 PRODUCT PORTFOLIO OF CELERA DIAGNOSTICS.....</i>	<i>129</i>
<i>TABLE 106 NEW PRODUCT DEVELOPMENT OF CELERA</i>	
<i>DIAGNOSTICS.....</i>	<i>130</i>
STRATEGY.....	130
CEPHEID.....	130
OVERVIEW.....	130
<i>TABLE 107 PRODUCT PORTFOLIO OF CEPHEID.....</i>	<i>131</i>
<i>TABLE 107 (CONTINUED).....</i>	<i>132</i>
<i>TABLE 107 (CONTINUED).....</i>	<i>133</i>
STRATEGY.....	133
CLINICAL DATA.....	133
OVERVIEW.....	134
<i>TABLE 108 PRODUCT PORTFOLIO OF CLINICAL DATA.....</i>	<i>134</i>
<i>TABLE 108 (CONTINUED).....</i>	<i>135</i>
STRATEGY.....	135
CURAGEN CORP.....	135
OVERVIEW.....	136
<i>TABLE 109 PRODUCT PORTFOLIO OF CURAGEN CORP.....</i>	<i>136</i>
STRATEGY.....	136
DAKO DENMARK A/S.....	136
OVERVIEW.....	137
<i>TABLE 110 PRODUCT PORTFOLIO OF DAKO DENMARK A/S.....</i>	<i>137</i>
<i>TABLE 110 (CONTINUED).....</i>	<i>138</i>
STRATEGY.....	138
DECODE GENETICS.....	138
OVERVIEW.....	138
<i>TABLE 111 PRODUCT PORTFOLIO OF DECODE GENETICS.....</i>	<i>139</i>
<i>TABLE 112 NEW PRODUCT DEVELOPMENT OF DECODE GENETICS....</i>	<i>140</i>
STRATEGY.....	140
DNA DIRECT, INC.....	141
OVERVIEW.....	141
<i>TABLE 113 PRODUCT PORTFOLIO OF DNA DIRECT, INC.....</i>	<i>141</i>
STRATEGY.....	142
DXS LTD.....	142
OVERVIEW.....	142
<i>TABLE 114 PRODUCT PORTFOLIO OF DXS LIMITED.....</i>	<i>143</i>
STRATEGY.....	143
EXACT SCIENCES CORP.....	144
OVERVIEW.....	144
<i>TABLE 115 PRODUCT PORTFOLIO OF EXACT SCIENCES CORP.....</i>	<i>144</i>
STRATEGY.....	145

EXAGEN DIAGNOSTICS .....	145
OVERVIEW .....	145
<i>TABLE 116 PRODUCT PORTFOLIO OF EXAGEN DIAGNOSTICS .....</i>	<i>145</i>
GENE LOGIC (AN OCIMUM BIOSOLUTIONS COMPANY) .....	146
OVERVIEW .....	146
<i>TABLE 117 PRODUCT PORTFOLIO OF GENE LOGIC.....</i>	<i>146</i>
<i>TABLE 117 (CONTINUED).....</i>	<i>147</i>
STRATEGY.....	148
GENELEX CORP.....	148
OVERVIEW .....	148
<i>TABLE 118 PRODUCT PORTFOLIO OF GENELEX CORP.....</i>	<i>148</i>
<i>TABLE 118 (CONTINUED).....</i>	<i>149</i>
<i>TABLE 118 (CONTINUED).....</i>	<i>150</i>
STRATEGY.....	150
GENENTECH, INC. ....	150
OVERVIEW .....	151
<i>TABLE 119 PRODUCT PORTFOLIO OF GENENTECH, INC. ....</i>	<i>151</i>
<i>TABLE 119 (CONTINUED).....</i>	<i>152</i>
STRATEGY.....	152
GENOMIC HEALTH, INC. ....	152
OVERVIEW .....	152
<i>TABLE 120 PRODUCT PORTFOLIO OF GENOMIC HEALTH INC .....</i>	<i>153</i>
STRATEGY.....	153
GEN-PROBE .....	153
OVERVIEW .....	153
<i>TABLE 121 PRODUCT PORTFOLIO OF GEN-PROBE.....</i>	<i>154</i>
<i>TABLE 121 (CONTINUED).....</i>	<i>155</i>
<i>TABLE 121 (CONTINUED).....</i>	<i>156</i>
<i>TABLE 122 NEW PRODUCT DEVELOPMENT OF GEN-PROBE.....</i>	<i>157</i>
STRATEGY.....	157
GENTA .....	157
OVERVIEW .....	157
<i>TABLE 123 PRODUCT PORTFOLIO OF GENTA .....</i>	<i>158</i>
<i>TABLE 124 NEW PRODUCT DEVELOPMENT OF GENTA .....</i>	<i>158</i>
STRATEGY.....	158
GLAXOSMITHKLINE.....	159
OVERVIEW .....	159
<i>TABLE 125 PRODUCT PORTFOLIO OF GLAXOSMITHKLINE .....</i>	<i>159</i>
STRATEGY.....	159
ILLUMINA.....	160
OVERVIEW .....	160
<i>TABLE 126 PRODUCT PORTFOLIO OF ILLUMINA .....</i>	<i>160</i>
<i>TABLE 126 (CONTINUED).....</i>	<i>161</i>
STRATEGY.....	161



LUMINEX CORP.....	161
OVERVIEW .....	162
<i>TABLE 127 PRODUCT PORTFOLIO OF LUMINEX CORP.</i> .....	<i>162</i>
MILLENNIUM.....	162
OVERVIEW .....	163
<i>TABLE 128 PRODUCT PORTFOLIO OF MILLENNIUM</i> .....	<i>163</i>
STRATEGY.....	163
MONOGRAM BIOSCIENCES .....	163
OVERVIEW .....	163
<i>TABLE 129 PRODUCT PORTFOLIO OF MONOGRAM BIOSCIENCES</i> .....	<i>164</i>
STRATEGY.....	165
MYRIAD GENETICS, INC.....	165
OVERVIEW .....	165
<i>TABLE 130 PRODUCT PORTFOLIOS OF MYRIAD GENETICS</i> .....	<i>165</i>
<i>TABLE 130 (CONTINUED)</i> .....	<i>166</i>
<i>TABLE 130 (CONTINUED)</i> .....	<i>167</i>
<i>TABLE 131 NEW PRODUCT DEVELOPMENT OF MYRIAD GENETICS</i> .....	<i>167</i>
STRATEGY.....	167
NANOGEN.....	168
OVERVIEW .....	168
<i>TABLE 132 PRODUCT PORTFOLIO OF NANOGEN</i> .....	<i>168</i>
<i>TABLE 132 (CONTINUED)</i> .....	<i>169</i>
STRATEGY.....	169
NOVARTIS.....	169
OVERVIEW .....	170
<i>TABLE 133 PRODUCT PORTFOLIO OF NOVARTIS</i> .....	<i>170</i>
STRATEGY.....	170
OSMETECH PLC.....	171
OVERVIEW .....	171
<i>TABLE 134 PRODUCT PORTFOLIO OF WYETH</i> .....	<i>171</i>
STRATEGY.....	171
PROMEGA .....	172
OVERVIEW .....	172
<i>TABLE 135 PRODUCT PORTFOLIO OF PROMEGA</i> .....	<i>172</i>
<i>TABLE 135 (CONTINUED)</i> .....	<i>173</i>
<i>TABLE 135 (CONTINUED)</i> .....	<i>174</i>
STRATEGY.....	175
QIAGEN .....	175
OVERVIEW .....	175
<i>TABLE 136 PRODUCT PORTFOLIO OF QIAGEN</i> .....	<i>176</i>
<i>TABLE 136 (CONTINUED)</i> .....	<i>177</i>
STRATEGY.....	177
ROCHE DIAGNOSTICS.....	178
OVERVIEW .....	178

<i>TABLE 137 PRODUCT PORTFOLIO OF ROCHE DIAGNOSTICS</i> .....	178
<i>TABLE 137 (CONTINUED)</i> .....	179
STRATEGY.....	180
SIEMENS HEALTHCARE DIAGNOSTICS.....	180
OVERVIEW .....	180
<i>TABLE 138 PRODUCT PORTFOLIO OF SIEMENS HEALTHCARE</i>	
<i>DIAGNOSTICS</i> .....	180
<i>TABLE 138 (CONTINUED)</i> .....	181
STRATEGY.....	181
TARGET DISCOVERY, INC. ....	181
OVERVIEW .....	181
<i>TABLE 139 PRODUCT PORTFOLIO OF TARGET DISCOVERY</i> .....	182
STRATEGY.....	182
VENTANA MEDICAL SYSTEMS, INC.....	182
OVERVIEW .....	182
<i>TABLE 140 PRODUCT PORTFOLIO OF VENTANA</i>	
<i>MEDICALSYSTEMS, INC.</i> .....	183
STRATEGY.....	183
WYETH .....	184
OVERVIEW .....	184
<i>TABLE 141 PRODUCT PORTFOLIO OF WYETH</i> .....	184
STRATEGY.....	184
APPENDIX .....	185
PATENTS ISSUED IN U.S. ....	185
<i>TABLE 142 PATENTS ISSUED IN THE UNITED STATES</i> .....	185
<i>TABLE 142 (CONTINUED)</i> .....	186
<i>TABLE 142 (CONTINUED)</i> .....	187
<i>TABLE 142 (CONTINUED)</i> .....	188
<i>TABLE 142 (CONTINUED)</i> .....	189
<i>TABLE 142 (CONTINUED)</i> .....	190
<i>TABLE 142 (CONTINUED)</i> .....	191
PATENTS ISSUED IN EUROPE.....	192
<i>TABLE 143 PATENTS ISSUED IN EUROPE</i> .....	192
PATENTS ISSUED IN JAPAN.....	193
TABLE 144 PATENTS ISSUED IN JAPAN .....	193